Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

Keith Leiper, Kate Martin, Anthony Ellis, Sreedhar Subramanian, Alastair J Watson, Steve E Christmas, Deborah Howarth, Fiona Campbell, Jonathan M Rhodes

Research output: Contribution to journalArticlepeer-review

107 Citations (Scopus)


To assess the safety and efficacy of the B lymphocyte (anti-CD20) antibody, rituximab, in the treatment of steroid-resistant moderately active ulcerative colitis (UC).
Original languageEnglish
Pages (from-to)1520-1526
Number of pages7
Issue number11
Publication statusPublished - Nov 2011


  • Adult
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD19
  • Antigens, CD20
  • B-Lymphocytes
  • Colitis, Ulcerative
  • Colon
  • Female
  • Glucocorticoids
  • Humans
  • Immunohistochemistry
  • Immunosuppressive Agents
  • Lymphocyte Count
  • Middle Aged
  • Remission Induction

Cite this